XRCC1 helps prevent harmful PARP1 capturing through DNA foundation excision fix

02). Those with low tumor CD31 expression had a longer median DFS than patients with high tumor CD31 expression (p=0.019). There was no correlation between Ang-1 expression and DFS. The expression of biomarkers in normal kidney tissue was significantly lower than in tumor tissue (p less then 0.001). In conclusion, higher VEGF scores and greater CD31 expression were associated with longer DFS, but neither of these biomarkers correlated with progression-free survival or overall survival.Electrically conducting nanospheres of poly(3,4-ethylenedioxythiophene)poly(styrene sulfonate) (PEDOTPSS) with tailored size were prepared using a solvent displacement technique. To fabricate these nanostructures, dried PEDOTPSS was dissolved in ethylene glycol (EG) and the solution was precipitated in deionized water. The proposed fabrication route allowed obtaining a water-based dispersion of PEDOTPSS nanospheres with good optical properties. To determine the physical properties of the nanospheres, we followed a nanoscale approach, using atomic force microscopy. Our nanoscale mechanical and electrical investigations showed that the nanospheres retained good physical and conductivity properties, compared to the commercial product. Moreover, the local studies indicated that the reprecipitation process and the spherical shape lead to a different arrangement of the PSS and PEDOT phases.
Acne vulgaris (acne) is a common, complex, multifactorial disorder. Various expressions of acne in childhood can be categorized by age, severity, and pubertal status.
To improve pediatric acne patients’ outcomes, various expressions of pediatric acne to educate and tailor nonprescription acne treatment and skincare using cleansers and moisturizers were defined and discussed.
An expert panel of pediatric dermatologists and dermatologists reviewed and discussed nonprescription acne treatment and skincare literature. The results from the literature searches were used together with the panel’s expert opinion and experience to adopt various expressions of pediatric acne and prevention, treatment, and maintenance of the condition using nonprescription acne treatment and skincare.
The panel agreed on sixteen acne patient profiles addressing various age categories of pediatric acne neonatal acne birth to ≤ 8 weeks; infantile acne 8 weeks to ≤1 year; mid-childhood acne 1 year to <7 years; preadolescent acne ≥7 to 12 years; adolescent acne ≥12 to 19 years or after menarche for girls. Nonprescription acne treatment and skincare products containing lipids such as ceramides play an important role in monotherapy, adjunctive, and maintenance treatment; however, their role in pediatric acne is not well defined and requires more studies.
Pediatric acne deserves more attention from healthcare providers treating children regarding differential diagnosis, treatment, and maintenance using nonprescription acne treatment and skincare. J Drugs Dermatol. 2022;21(6)602-612. doi10.36849/JDD.6872.
Pediatric acne deserves more attention from healthcare providers treating children regarding differential diagnosis, treatment, and maintenance using nonprescription acne treatment and skincare. J Drugs Dermatol. 2022;21(6)602-612. doi10.36849/JDD.6872.Acne vulgaris is a multifactorial chronic disorder of the pilosebaceous unit. Established treatments include topical retinoids, antibiotics in mild cases, and oral antibiotics and isotretinoin in moderate to severe cases. Anti-androgens and other hormonal therapies constitute another group of drugs in the armamentarium of acne management. These can be used in patients who do not respond to the aforementioned treatments or when other systemic drugs cannot be tolerated. Recent approval of topical androgen receptor blocker is an additional armamentarium for the management of acne. Considering limited systemic exposure and good efficacy, it has potential for wide usage in patients with acne. In this article, we critically review currently available hormonal treatment options based on published literature search of an electronic database (MEDLINE/PubMed) performed through June 2021. J Drugs Dermatol. 2022;21(6)618-623. doi10.36849/JDD.6494.In July 2022, I will reach the milestone of practicing dermatology for 36 years, with 30 years of experience also devoted to clinical research. My background in pharmacy before attending medical school set the stage for my strong interest in therapeutics with regular participation in educational initiatives at many meetings and in multiple peer-reviewed publications addressing several therapeutic areas. Ultimately, my primary interest is to translate important advances in our understanding of common chronic skin diseases and/or their management to dermatology clinicians who practice day-to-day in the trenches.
While rosacea is a common inflammatory condition that affects diverse populations, published data in skin of color (SOC) are limited. This review explored nuances in clinical presentation and treatment considerations in SOC patients with rosacea and the role of cleansers and moisturizers in the management of rosacea in these populations.
A panel reviewed and discussed aspects of rosacea in SOC and possible implications for treatment and maintenance. The outcome of these discussions, coupled with the panel's expert opinion and experience was used to define draft statements. After group discussions and an online review process, the panel agreed on the inclusion and wording of five statements.
Studies and anecdotal clinical experience suggest that rosacea is more common in SOC populations than previously reported. The clinical presentation of rosacea across diverse skin types includes the spectrum of clinical subtypes observed in other populations; however, clinical features may be less conspicuous in individuals with higher skin phototypes and the index of suspicion may be lower in SOC populations. ABT-199 molecular weight To avoid underdiagnosis, dermatologists should consider rosacea in the differential diagnosis of any patient presenting with a history of skin sensitivity, central facial erythema, papules, and pustules. The compromised barrier in rosacea contributes to skin sensitivity. Studies including Chinese rosacea patients showed that using a moisturizer and sunscreen negatively correlated with rosacea development.
The use of skincare could improve rosacea symptomatology. These products are recommended before and during prescription therapy and as part of a maintenance regimen as adjuncts. J Drugs Dermatol. 2022;21(6)574-580. doi10.36849/JDD.6838.
The use of skincare could improve rosacea symptomatology. These products are recommended before and during prescription therapy and as part of a maintenance regimen as adjuncts. J Drugs Dermatol. 2022;21(6)574-580. doi10.36849/JDD.6838.The growing interest in improving the quality of body (as distinct from facial) skin may be in part attributable to the expanding use of noninvasive body contouring procedures. In this review, we describe a new framework characterizing the factors that define skin quality (including visual, textural, and biomechanical attributes) that provides a foundation for improved assessment of skin quality and its response to treatment. We then highlight critical biological pathways responsible for body skin restoration and maintenance that have been identified during the development of restorative topical products. Each of these pathways, including extracellular matrix support, suppression of lipogenesis, and enhancement of cellular/macromolecular recycling and clearance, lymphatic drainage, and lipolysis, is a potential target of 1 or more bioactive substances. A survey of available topical products marketed for skin quality improvement suggests that none target more than 2 of these pathways (including extracellular matrix support, lipolysis, and autophagy, a component of cellular recycling), leaving abundant opportunity for development of new topical formulations that target all or most of the critical pathways. Such formulations may provide improved outcomes when used as standalone products for general skin quality improvement and rejuvenation, in addition to their potential for post-procedure use, and also for pre-procedure skin conditioning. J Drugs Dermatol. 2022;21(6)653-658. doi10.36849/JDD.6811.
Biologic drugs are generally recommended for treating moderate-to-severe psoriasis. While eligibility criteria are primarily defined by clinical treatment guidelines, access to these therapies varies between European countries and is regulated by country-specific reimbursement criteria. This post-hoc subgroup analysis of integrated data from two phase III trials (UNCOVER-2 and -3) reports the efficacy of ixekizumab relative to that of etanercept in patients with moderate-to-severe plaque psoriasis selected into groups defined by original reimbursement criteria from eight European countries.
This analysis included baseline and 12-week data from the ixekizumab- and etanercept-treated study populations from UNCOVER-2 and -3. Patients were classified as meeting/not meeting each country-specific biologic eligibility criterion. Efficacy was defined by Psoriasis Area and Severity Index (PASI) 75, 90, and 100 response rates and by Dermatology Life Quality Index (DLQI) (0,1) response rates. Treatment responses acrercept, in patients with moderate-to-severe psoriasis across a range of European biologic treatment reimbursement eligibility criteria provides new insights to inform treatment decisions in clinical practice. J Drugs Dermatol. 2022;21(6)659-667. doi10.36849/JDD.6620.
Acne vulgaris is very common among adolescents and young adults. It is important for clinicians who provide care to these patients to have a plan of action for assessing and managing acne in daily practice.
Post-hoc analysis of two large-scale phase 3 pivotal trials of trifarotene 0.005% cream, focusing on efficacy, safety, and tolerability in the subgroup of subjects aged 12 to 17, inclusive.
Trifarotene was effective and well tolerated on both the face and trunk in patients ages 12-17 with moderate acne. There was a low and acceptable rate of adverse events and tolerability was favorable.
Trifarotene monotherapy was associated with good clinical efficacy, safety, and tolerability. Once-daily application offers convenience for patients, and the low concentration of trifarotene makes it well-suited to use on large skin areas such as the trunk. J Drugs Dermatol. 2022;21(6)582-586. doi10.36849/JDD.6778.
Trifarotene monotherapy was associated with good clinical efficacy, safety, and tolerability. Once-daily application offers convenience for patients, and the low concentration of trifarotene makes it well-suited to use on large skin areas such as the trunk. J Drugs Dermatol. 2022;21(6)582-586. doi10.36849/JDD.6778.
Recent changes to the iPLEDGE platform left providers without the ability to prescribe isotretinoin to their patients. A potential substitute for isotretinoin could be beneficial when the drug is unavailable. Prior to the FDA approval of isotretinoin, a vitamin A derivative, vitamin A was studied for its use in acne management.
To review the potential of vitamin A to serve as a substitute for isotretinoin when the latter drug is inaccessible.
We conducted a review of published literature from 1931 to 2021, regarding the use of vitamin A in acne treatment, using PubMed and Google Scholar databases. Nine studies were selected after reviewing articles for relevancy to our topic.
Eight out of the 9 studies noted improvement in patients’ acne with vitamin A use. Ranges of doses used were 36,000 I/U daily to 500,000 I/U daily, with 100,000 I/U daily being the most common. Side effects were mainly mucocutaneous in nature.
Many of the trials included in our review were published over 50 years prior and lack standardized components of clinical trials today.